回顾前列腺癌 (PCa) 局部治疗 (FT) 后挽救治疗的文献。我们在 PubMed、Scopus 和 Web of Science 上进行了截至 2024 年 3 月 15 日的非系统文献回顾，评估了挽救治疗的研究初次 FT 后复发 PCa 患者的结果。纳入了超过 10 名患者的原始前瞻性和回顾性研究。评论、编辑评论、会议摘要和仅关注全腺治疗的研究被排除在外。共纳入了 21 项研究，涉及 1012 名患者。最报道的挽救治疗是挽救性根治性前列腺切除术，然后重新进行消融治疗。只有一项研究评估了挽救性放射治疗。除一项前瞻性研究外，所有研究均为回顾性研究。肿瘤学结果显示生化复发率可接受。功能结果各不相同，尽管失禁率受到的影响较小，但各种方式对勃起功能都有显着影响。所有治疗方案的并发症普遍较低。初次 FT 后的挽救治疗是可行、安全的，并且具有合理的肿瘤学结果。然而，性功能显着下降很常见，而节制受到的影响相对较小。文献主要由回顾性研究组成；因此，未来的研究应侧重于大规模的前瞻性评估，以更好地定义治疗方案并改善患者的治疗结果。© 2024。作者，获得 Springer Nature Limited 的独家许可。

To review the literature on salvage treatments after focal therapy (FT) for prostate cancer (PCa).A non-systematic literature review was conducted on PubMed, Scopus, and Web of Science up to March 15, 2024, for studies that assessed salvage treatment outcomes in patients with recurrent PCa after primary FT. Original prospective and retrospective studies with more than 10 patients were included. Reviews, editorial comments, conference abstracts, and studies focusing solely on whole-gland treatments were excluded.Twenty-one studies with a total of 1012 patients were included. The most reported salvage treatments were salvage radical prostatectomy followed by re-do ablation therapy. Only one study evaluated salvage radiation therapy. Except for one prospective study, all studies were retrospective. Oncological outcomes showed acceptable biochemical recurrence rates. Functional outcomes varied, with significant impacts observed on erectile function across modalities, though continence rates were less impacted. Complications were generally low across all treatment options.Salvage treatment post-primary FT is feasible, safe, and has reasonable oncologic outcomes. However, significant declines in sexual function are common, while continence is comparatively less affected. The literature primarily consists of retrospective studies; hence, future research should focus on large-scale prospective evaluations to better define treatment protocols and improve patient outcomes.© 2024. The Author(s), under exclusive licence to Springer Nature Limited.